局部放射治疗对酪氨酸激酶抑制剂治疗非小细胞肺癌伴寡残留病变的影响OA
Impact of local radiotherapy on tyrosine kinase inhibitor treatment in non-small cell lung cancer with oligo-residual disease
目的 分析局部放射治疗(LT)在经酪氨酸激酶抑制剂(TKI)治疗后出现寡残留病灶的晚期非小细胞肺癌(NSCLC)患者中的临床价值.方法 回顾性纳入 2018 年 2 月至 2024 年 5 月在北京协和医院接受靶向治疗并发展为寡残留病变的 61 例Ⅳ期NSCLC患者,将其分成局部放射治疗组(n=31,应用局部巩固治疗或局部消融治疗,期间继续全身治疗)和非局部放射治疗组(n=30,仅应用全身治疗).比较两组无进展生存期(PFS)、总生存期(QS)及局部放射治疗组安全性.结果 局部放射治疗组较非局部放射治疗组改善无进展生存期(31 个月比 23 个月,P=0.171),但未达到统计学差异.接受局部放射治疗的患者总生存期更长(54 个月比 42 个月,P=0.713),但未达到统计学差异.同时局部放射治疗组共 7 例患者(22.6%)发生任何级别的放射性肺炎,其中 4 例(12.9%)发生 1 级肺炎,3 例(9.7%)发生2 级肺炎.单因素及多因素分析显示转移灶数目、性别、ECOG评分、TKI类型以及靶向治疗获得的最佳疗效可以影响患者预后,其中ECOG评分和吸烟状态是PFS的独立影响因素.结论 经TKI治疗后出现寡残留病灶的NSCLC患者中,应用局部放射治疗初步显示可能延长PFS,且未显著增加不良反应.
Objective To evaluate the clinical significance of local radiotherapy(LT)in oligo-residual lesions of advanced non-small cell lung cancer(NSCLC)treated with tyrosine kinase inhibitors(TKIs).Methods A retro-spective study was conducted in 61 patients with stage Ⅳ NSCLC who developed oligo-residual disease after TKI therapy at Peking Union Medical College Hospital from February 2018 to May 2024.The patients were stratified into two groups:the LT group(n=31,receiving local consolidative therapy or ablation while continuing systemic thera-py)and the non-LT group(n=30,receiving systemic therapy alone).Progression-free survival(PFS),overall sur-vival(OS),and treatment-related safety were compared between the groups.Results The LT group showed a pro-longed PFS compared to the non-LT group(31 vs.23 months,P=0.171),although the difference did not reach statistical significance.Patients undergoing LT also had a longer median OS(54 vs.42 months,P=0.713),although the difference did not achieve statistical significance.A total of 7 patients(22.6%)in the local radiotherapy group developed radiation pneumonitis of any grade,including 4 patients(12.9%)with grade 1 pneumonitis and 3 patients(9.7%)with grade 2 pneumonitis.Univariate and multivariate analyses indicated that the number of meta-static lesions,sex,ECOG performance status,targeted therapy regimen,and best response to targeted therapy were factors associated with patient prognosis.Among these variables,ECOG performance status and smoking status were identified as independent predictors of PFS.Conclusions In NSCLC patients with oligo-residual lesions after TKI therapy,LT preliminarily appears to prolong progression-free survival without significantly increasing treatment-re-lated adverse events.
刘芃芃;孙昭;邱维;唐辉;朱文佳;王文惠;王颖轶
中国医学科学院北京协和医学院 北京协和医院 肿瘤内科,北京 100730中国医学科学院北京协和医学院 北京协和医院 肿瘤内科,北京 100730中国医学科学院北京协和医学院 北京协和医院 肿瘤内科,北京 100730中国医学科学院北京协和医学院 北京协和医院 肿瘤内科,北京 100730中国医学科学院北京协和医学院 北京协和医院 核医学科,北京 100730中国医学科学院北京协和医学院 北京协和医院 放射治疗科,北京 100730中国医学科学院北京协和医学院 北京协和医院 肿瘤内科,北京 100730
医药卫生
非小细胞肺癌靶向治疗寡残留病变局部巩固治疗局部消融治疗
non-small cell lung cancertargeted therapyoligo-residual diseaselocal consolidative therapylocal ablative therapy
《基础医学与临床》 2026 (4)
491-497,7
评论